On the fly News and insights, exclusive to thefly.com


Vertex Pharmaceuticals

$216.82 /

+3.33 (+1.56%)


Vertex falls after ending development of liver disease drug VX-864

Vertex Pharmaceuticals is trading lower after the company announced that VX-864 will not advance into late-stage development. Vertex said that in a Phase 2 proof-of-concept study, VX-864 achieved statistically significant increases in mean functional alpha-1 antitrypsin levels of 2.2 to 2.3 micromolar from baseline in people with alpha-1 antitrypsin deficiency with the PiZZ genotype, across three dose groups of VX-864 compared to placebo. It added, however: "Although results provide proof-of-mechanism, the magnitude of treatment effect observed in this study is unlikely to translate into substantial clinical benefit. As such, Vertex will not advance VX-864 into late-stage development and instead will advance additional novel small molecule correctors with the potential for increased clinical efficacy into the clinic." Vertex shares in after-hours trading are down 11%, or $24.77, to $192.00.

VRTX Vertex Pharmaceuticals
$216.82 /

+3.33 (+1.56%)

04/21/21 Jefferies
Jefferies upgrades Crispr Therapeutics to Buy after Vertex deal renegotiated
04/21/21 Barclays
Crispr Therapeutics price target raised to $160 from $140 at Barclays
04/20/21 Chardan
Amended pact may show Vertex confidence in Crisper program, says Chardan
03/25/21 Citi
Citi likes share setup for Vertex Pharmaceuticals, adds to Focus List

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.